The cell-line-derived subcutaneous tumor model in preclinical cancer research

被引:45
|
作者
Stribbling, Stephen M. [1 ]
Ryan, Anderson J. [1 ]
机构
[1] Univ Oxford, Dept Oncol, Oxford, England
关键词
GROWTH-FACTOR; HUMAN BREAST; IN-VIVO; ANTITUMOR-ACTIVITY; XENOGRAFT MODELS; PROSTATE-CANCER; T-CELLS; POTENT ANTITUMOR; MOUSE MODELS; NUDE-MICE;
D O I
10.1038/s41596-022-00709-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Tumor-bearing experimental animals are essential for preclinical cancer drug development. A broad range of tumor models is available, with the simplest and most widely used involving a tumor of mouse or human origin growing beneath the skin of a mouse: the subcutaneous tumor model. Here, we outline the different types of in vivo tumor model, including some of their advantages and disadvantages and how they fit into the drug-development process. We then describe in more detail the subcutaneous tumor model and key steps needed to establish it in the laboratory, namely: choosing the mouse strain and tumor cells; cell culture, preparation and injection of tumor cells; determining tumor volume; mouse welfare; and an appropriate experimental end point. The protocol leads to subcutaneous tumor growth usually within 1-3 weeks of cell injection and is suitable for those with experience in tissue culture and mouse experimentation. The authors describe a protocol for growing a tumor of mouse or human origin beneath the skin of a mouse, which is widely known as the subcutaneous mouse tumor model.
引用
收藏
页码:2108 / 2128
页数:21
相关论文
共 50 条
  • [1] The cell-line-derived subcutaneous tumor model in preclinical cancer research
    Stephen M. Stribbling
    Anderson J. Ryan
    Nature Protocols, 2022, 17 : 2108 - 2128
  • [2] Development of a cell-line-derived cfDNA Prostate Cancer NGS reference material for liquid biopsy and MRD
    Pavlova, Mila
    Freeman, Bernice
    Farace, Ilaria
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 286 - 287
  • [3] CK1α-targeting inhibits primary and metastatic colorectal cancer in vitro, ex vivo, in cell-line-derived and patient-derived tumor xenograft mice models
    Ren, Fupeng
    Zhu, Jingwen
    Li, Kesang
    Cheng, Yiquan
    Zhu, Xiyan
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (03) : 1903 - 1913
  • [4] Human glial cell-line-derived neurotrophic factor: A structure-function analysis
    Chen, ZY
    He, ZY
    He, C
    Lu, CL
    Wu, XF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 268 (03) : 692 - 696
  • [5] CHEMOTHERAPY OF CELL-LINE-DERIVED HUMAN COLON CARCINOMAS IN MICE IMMUNOSUPPRESSED WITH ANTITHYMOCYTE-SERUM
    TIBBETTS, LM
    CHU, MY
    HAGER, JC
    DEXTER, DL
    CALABRESI, P
    CANCER, 1977, 40 (05) : 2651 - 2659
  • [6] Differential in vivo effects olf neurturin and glial cell-line-derived neurotrophic factor
    Hoane, MR
    Gulwadi, AG
    Morrison, S
    Hovanesian, G
    Lindner, MD
    Tao, W
    EXPERIMENTAL NEUROLOGY, 1999, 160 (01) : 235 - 243
  • [7] Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR
    Hasan, Tahrim
    Carter, Beverley
    Denic, Nash
    Gai, Luis
    Power, Jennifer
    Voisey, Kim
    Kao, K. R.
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (09) : 746 - 751
  • [8] Preclinical model of patient derived tumor transplant in humanized mice for cancer immunotherapy
    Wulf-Goldenberg, Annika
    Stecklum, Maria
    Fichtner, Iduna
    Hoffmann, Jens
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [9] A new model of patient tumor-derived breast cancer Xenografts for preclinical assays
    Marangoni, Elisabetta
    Vincent-Salomon, Anne
    Auger, Nathalie
    Degeorges, Armelle
    Assayag, Franck
    de Cremoux, Patricia
    De Plater, Ludmilla
    Guyader, Charlotte
    De Pinieux, Gonzague
    Judde, Jean-Gabriel
    Rebucci, Magali
    Tran-Perennou, Carine
    Sastre-Garau, Xavier
    Sigal-Zafrani, Brigitte
    Delattre, Olivier
    Dieras, Veronique
    Poupon, Marie-France
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3989 - 3998
  • [10] Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib.
    Gagnon, Robert C.
    Liu, Yuan
    Choueiri, Toni K.
    Martin, Anne-Marie
    Rosenberg, Jonathan E.
    Signoretti, Sabina
    Pandite, Lini N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)